Organization
US Oncology Network/Virginia Oncology Associates
4 abstracts
Abstract
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,
Abstract
The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.Org: US Oncology Network/Virginia Cancer Specialists, Ontada, McKesson, US Oncology Network/Virginia Oncology Associates, New York Oncology Hematology-Albany,
Abstract
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.Org: US Oncology Network/Virginia Oncology Associates, Ontada, US Oncology Network, Virginia Cancer Specialists, US Oncology Network / Virginia Oncology Associates,
Abstract
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.Org: Institut de Cancérologie de l’Ouest Angers-Nantes, Washington University School of Medicine in St Louis, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Aichi Cancer Center Hospital, UCLA Jonsson Comprehensive Cancer Center,